Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis
Top Cited Papers
- 27 June 2005
- journal article
- Published by Springer Nature in Oncogene
- Vol. 24 (44) , 6646-6656
- https://doi.org/10.1038/sj.onc.1208822
Abstract
Thyroid cancer poses a significant clinical challenge, and our understanding of its pathogenesis is incomplete. To gain insight into the pathogenesis of papillary thyroid carcinoma, transcriptional profiles of four normal thyroids and 51 papillary carcinomas (PCs) were generated using DNA microarrays. The tumors were genotyped for their common activating mutations: BRAF V600E point mutation, RET/PTC1 and 3 rearrangement and point mutations of KRAS, HRAS and NRAS. Principal component analysis based on the entire expression data set separated the PCs into three groups that were found to reflect tumor morphology and mutational status. By combining expression profiles with mutational status, we defined distinct expression profiles for the BRAF, RET/PTC and RAS mutation groups. Using small numbers of genes, a simple classifier was able to classify correctly the mutational status of all 40 tumors with known mutations. One tumor without a detectable mutation was predicted by the classifier to have a RET/PTC rearrangement and was shown to contain one by fluorescence in situ hybridization analysis. Among the mutation-specific expression signatures were genes whose differential expression was a direct consequence of the mutation, as well as genes involved in a variety of biological processes including immune response and signal transduction. Expression of one mutation-specific differentially expressed gene, TPO, was validated at the protein level using immunohistochemistry and tissue arrays containing an independent set of tumors. The results demonstrate that mutational status is the primary determinant of gene expression variation within these tumors, a finding that may have clinical and diagnostic significance and predicts success for therapies designed to prevent the consequences of these mutations.Keywords
This publication has 72 references indexed in Scilit:
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Genome-Wide Profiling of Papillary Thyroid Cancer Identifies MUC1 as an Independent Prognostic MarkerCancer Research, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Gene-expression profiles predict survival of patients with lung adenocarcinomaNature Medicine, 2002
- Silencing of the PTEN tumor‐suppressor gene in anaplastic thyroid cancerGenes, Chromosomes and Cancer, 2002
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences, 2001
- Molecular pathogenesis of thyroid nodules and cancerBest Practice & Research Clinical Endocrinology & Metabolism, 2000
- Ras Oncogene Mutations in Thyroid TumorsDiagnostic Molecular Pathology, 1996
- Thyroid Peroxidase Expression and DNA Polymorphisms in Thyroid CancerBiochemical and Biophysical Research Communications, 1994
- Asymptotics for and against cross-validationBiometrika, 1977